A guide to how breast cancers are staged, from in situ (stage 0) to metastatic (stage IV).

"/> Cure Magazine
ADVERTISEMENT

What Stage Is Your Breast Cancer?

A guide to how breast cancers are staged, from in situ (stage 0) to metastatic (stage IV).

$author$
PUBLISHED FRIDAY, APRIL 20, 2007

Breast cancer is staged based on the size of the tumor and if and where it has spread, including nearby lymph nodes or distant organs of the body. Staging is defined as TNM: T for tumor size (0 to 4); N for lymph node involvement (0 to 3); M for whether the cancer has spread, or metastasized, to distant organs (0 or 1). Once these attributes have been determined, an overall stage of 0, 1, 2, 3 or 4 (also written as Roman numerals) is assigned.

Stage 0: About 62,000 women will be diagnosed this year with what is called in situ breast cancer—abnormal cells that have not spread from the milk ducts or lobules. Ductal carcinoma in situ is cancerous cells contained within the milk ducts, usually treated with breast-conserving surgery and radiation, or mastectomy. Lobular carcinoma in situ is when precancerous cells are contained in the lobes. Women with LCIS are at high risk for invasive cancer and may be prescribed tamoxifen to prevent further development of the abnormal cells and are advised to increase the frequency of clinical exams.

Stage 1: The tumor measures less than 2 centimeters. Although cancer cells have invaded the fatty or connective tissue, the cancer has not spread outside the breast. Breast-conserving surgery or mastectomy, along with an examination of nearby lymph nodes for errant cancer cells is recommended treatment.

Stage 2A: Tumors can be as large as 5 centimeters without lymph node involvement or less than 2 centimeters but has spread to nearby lymph nodes underneath the arm (called axillary nodes).

Stage 2B: The tumor is between 2 and 5 centimeters and cancer cells have invaded one to three nearby nodes. The tumor can be larger than 5 centimeters as long as it has not invaded axillary nodes.

Stage 3A: The tumor is smaller than 5 centimeters, but has spread to four to nine axillary nodes, which have grown together or into other nearby structures; or the cancer is larger than 5 centimeters and has spread to one to nine axillary nodes.

Stage 3B: The tumor has extended into the chest wall, skin or the ribs and may have spread to no lymph nodes or to as many as nine axillary nodes. It may have spread to internal mammary lymph nodes found on the inside of the chest along the breast bone.

Stage 3C: The cancer has spread to the lymph nodes located above the collarbone and at the base of the neck, or to 10 or more axillary nodes. Inflammatory breast cancer is classified as stage 3 unless it has spread to distant sites, which moves its classification to stage 4.

Stage 4: Cancer cells have traveled to distant nodes and organs of the body, including the brain, lung or liver; considered metastatic breast cancer.

ADVERTISEMENT
Related Articles
Success Fuels Researcher's Dreams of Helping Patients With Breast Cancer
Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Study Shows Women with Stage 1 HER2-Positive Breast Cancers Could Benefit from Herceptin
BY CHRISTINA IZZO
Results of a phase 2 study showed that women with small, stage 1 HER2-positive breast cancer who received a combination of lower-intensity chemotherapy and Herceptin following surgery were highly unlikely to have a recurrence.
Related Videos
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$